Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA COVID-19 vaccine (S-protein chimera)
- Development stage
- Unknown
- Lead developer
- Walvax Biotechnology
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The mRNA COVID-19 vaccine (S-protein chimera) is an mRNA-based vaccine designed to combat SARS-CoV-2 variants. It utilizes a chimeric spike (S) protein design, incorporating genetic material from different sarbecoviruses or SARS-CoV-2 variants to elicit a broad immune response. The vaccine delivers messenger RNA (mRNA) into human cells, instructing them to produce these chimeric spike proteins. These proteins then act as antigens, prompting the immune system to generate neutralizing antibodies and T-cells, thereby providing protection against future viral infection. This approach aims to offer broader protection against existing and emerging SARS-CoV-2 variants, including Omicron. It is being developed by Walvax Biotechnology in collaboration with Fudan University and Shanghai Blue Lake Bio.
- Other names
- 新型冠状病毒变异株mRNA疫苗（S蛋白嵌合体）
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on mRNA COVID-19 vaccine (S-protein chimera).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA COVID-19 vaccine (S-protein chimera).